Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
Ron Ram(Tel Aviv University), Ronen Ben‐Ami(Tel Aviv University), Chen Karni(Tel Aviv University), Nino Kikozashvilli(Tel Aviv University), Chen Glait‐Santar(Tel Aviv University), Ofrat Beyar‐Katz(Rambam Health Care Campus), David Shasha(Tel Aviv University), Yael Bar‐On(Tel Aviv University), Tal Freund(Tel Aviv University), Odelia Amit(Tel Aviv University), David Hagin(University of Washington), Arie Apel(Tel Aviv University), Chava Perry(Tel Aviv University), Rinat Eshel(Tel Aviv University), Irit Avivi(Tel Aviv Sourasky Medical Center), Sigi Kay(Tel Aviv University), Noam Benyamini(Tel Aviv University), Ronit Gold(Tel Aviv University), Gabi Shefer(Tel Aviv Sourasky Medical Center)
Cited by 164
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses
|mBio|2020|445
Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
|Frontiers in Immunology|2018|186
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170